| 41. |
|
|
| 42. |
|
|
| 43. |
- Kjekshus, John, et al.
(författare)
-
Rosuvastatin in older patients with systolic heart failure.
- 2007
-
Ingår i: The New England journal of medicine. - 1533-4406. ; 357:22, s. 2248-61
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients. METHODS: A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the number of hospitalizations. RESULTS: As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). During a median follow-up of 32.8 months, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.83 to 1.02; P=0.12), and 728 patients and 759 patients, respectively, died (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.31). There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes. In a prespecified secondary analysis, there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P<0.001). No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group. CONCLUSIONS: Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310.)
|
|
| 44. |
|
|
| 45. |
- Mach, H., et al.
(författare)
-
New structure information on Mg-30, Mg-31 and Mg-32
- 2005
-
Ingår i: European Physical Journal A. - : Springer Science and Business Media LLC. - 1434-601X .- 1434-6001. ; 25, s. 105-109
-
Konferensbidrag (refereegranskat)abstract
- The fast timing beta gamma gamma(t) method was applied to investigate the level lifetimes in Mg-30,Mg-31,Mg-32. Levels in Mg have been populated in beta and beta-delayed neutron emission of Na, at the ISOLDE facility. From the gamma gamma coincidences a number of new states have been identified and new level schemes were constructed for 30 31,32 Mg. The following preliminary half lives have been determined: T-1/2 = 3.9(4) ns for the 1789 keV state in Mg-30, T-1/2 = 133(8) ps and 10.5(8) us for the 221 keV and 461 keV states in Mg-31, respectively, and T1/2 = 16(4) ps for the 885 keV level in 32Mg. The 1789 keV level was established as a candidate for the intruder 0(+) configuration in Mg-30 with a possible strong E0 branch to the ground state.
|
|
| 46. |
- Mineva, Milena, et al.
(författare)
-
A New us Isomer in 136Sb Produced in the Projectile Fission of 238U
- 2001
-
Ingår i: European Physical Journal A. Hadrons and Nuclei. - 1434-6001. ; 11, s. 9-13
-
Tidskriftsartikel (refereegranskat)abstract
- The neutron-rich isotope Sb-136 has been produced following the relativistic projectile fission of U-238 in an experiment performed at the Fragment Separator at GSI, Darmstadt. Delayed gamma -ray spectroscopy of the fission products has been performed after isotope separation. A new isomeric state in Sb-136 has been populated, and its lifetime measured as T-1/2 = 565(50) ns. Realistic and empirical shell-model calculations have been performed and are compared to the experimental observables.
|
|
| 47. |
- Nap, M, et al.
(författare)
-
Specificity and affinity of monoclonal antibodies against carcinoembryonic antigen.
- 1992
-
Ingår i: Cancer Research. - 0008-5472 .- 1538-7445. ; 52:8, s. 2329-39
-
Tidskriftsartikel (refereegranskat)abstract
- The binding specificities of 52 well-characterized monoclonal antibodies (Mabs) against carcinoembryonic antigen (CEA) from 12 different research groups were studied by immunohistochemistry and immuno flow cytometry. In addition, the binding constant for the interaction between Mab and CEA was determined by a solution-phase assay. Cryostat sections of colon carcinoma and normal colon, stomach, liver, pancreas, and spleen were studied by immunohistochemistry. Peripheral blood granulocytes, monocytes, and lymphocytes were assayed by immuno flow cytometry. The Mabs used here have previously been classified into five essentially nonoverlapping epitope groups (GOLD 1-5) (Cancer Res., 49: 4852-4858, 1989). Most Mabs cross-reacted with different normal tissues, ranging from highly cross-reactive Mabs (positive reaction with 8 of 9 discriminating tissues) to relatively specific Mabs (positive reaction with 1 of 9 discriminating tissues). Five Mabs (10%) were specific, reacting only with colon carcinoma, normal colon mucosa, and normal gastric foveola. There was a correlation between epitope group and binding specificity. Mabs with a high degree of CEA specificity almost exclusively belonged to epitope groups 1, 2, and 3, while highly cross-reactive Mabs belonged to epitope groups 4 and 5. There was no correlation between antibody specificity and affinity for CEA. Specific Mabs with high as well as low affinity were found.
|
|
| 48. |
- Olaizola, B., et al.
(författare)
-
High-sensitivity study of levels in Al-30 following beta decay of Mg-30
- 2016
-
Ingår i: PHYSICAL REVIEW C. - 2469-9985 .- 2469-9993. ; 94:5
-
Tidskriftsartikel (refereegranskat)abstract
- gamma-ray and fast-timing spectroscopy were used to study levels in Al-30 populated following the beta(-) decay of Mg-30. Five new transitions and three new levels were located in Al-30. A search was made to identify the third 1(+) state expected at an excitation energy of similar to 2.5 MeV. Two new levels were found, at 3163.9 and 3362.5 keV, that are firm candidates for this state. Using the advanced time-delayed (ATD) beta gamma gamma (t) method we have measured the lifetime of the 243.8-keV state to be T-1/2 = 15(4) ps, which implies that the 243.8-keV transition is mainly of M1 character. Its fast B(M1; 2(+) -> 3(+)) value of 0.10(3) W.u. is in very good agreement with the USD shell-model prediction of 0.090 W.u. The 1801.5-keV level is the only level observed in this study that could be a candidate for the second excited 2(+) state.
|
|
| 49. |
|
|
| 50. |
- Podolyak, Z., et al.
(författare)
-
gamma-ray spectroscopy with a He-8 beam
- 2003
-
Ingår i: Nuclear Instruments and Methods in Physics Research Section A. - : Elsevier BV. - 0168-9002 .- 1872-9576. ; 511:3, s. 354-359
-
Tidskriftsartikel (refereegranskat)abstract
- The He-8 + Pb-208 reaction was studied in the first experiment with the EXOGAM germanium detector array using beam delivered by the SPIRAL facility. gamma-rays from direct and fusion-evaporation reactions were observed with high resolution. gamma-gamma coincidence data were obtained at a beam intensity level of 105 8He particles per second. Specially designed absorbers and beam detectors could further reduce the background radiation by orders of magnitude.
|
|
